Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Adjuvant chemotherapy can improve overall survival in patients with high-risk, low-grade glioma

Adjuvant chemotherapy can improve overall survival in patients with high-risk, low-grade glioma

Scientists develop new method for targeted drug delivery to cancer cells

Scientists develop new method for targeted drug delivery to cancer cells

Scientists develop a method of targeted drug delivery to cancer cells

Scientists develop a method of targeted drug delivery to cancer cells

Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

HDAC6 inhibition could be promising therapeutic approach for peripheral neuropathies

HDAC6 inhibition could be promising therapeutic approach for peripheral neuropathies

Clearance of cancer cell debris via pro-resolving mediators can prevent tumor recurrence

Clearance of cancer cell debris via pro-resolving mediators can prevent tumor recurrence

Novel agents appear to halt growth and progression of Ewing sarcoma

Novel agents appear to halt growth and progression of Ewing sarcoma

St. Jude creates world’s largest collection of pediatric solid tumor samples

St. Jude creates world’s largest collection of pediatric solid tumor samples

HHMI scientists expand access to new resource for studying pediatric cancers

HHMI scientists expand access to new resource for studying pediatric cancers